Exelixis is expected to post quarterly earnings of $0.86 per share, a 14.7% year-over-year increase, on revenues of $635 million, up 11.7%, for the quarter ended June 2026. The Zacks Earnings ESP model indicates a positive surprise of +6.31%, as the Most Accurate Estimate is higher than the consensus, and the stock carries a Zacks Rank #2. Over the last four quarters, the company has beaten consensus EPS estimates each time. In the same industry, NovoCure is expected to report a loss of $0.30 per share on revenues of $174.11 million, with an Earnings ESP of +0.83% but a Zacks Rank #4, making a beat less predictable.
Exelixis IncExpected earnings beat and revenue growth, with positive ESP and Zacks Rank.
Novocure Ltd